ArticleOncogene1999
A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Salirasib Inhibits the Expression of Genes Involved in Fibrosis in Fibroblasts of Systemic Sclerosis Patients.Immunity, inflammation and disease · 2024Article
- KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.Cells · 2024Review
- Article
- From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers.Cancer biology & medicine · 2019Article
- An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.Cancer chemotherapy and pharmacology · 2018Article
- RAS Regulates the Transition from Naive to Primed Pluripotent Stem Cells.Stem cell reports · 2018Article
- Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Journal of gastrointestinal oncology · 2016Review
- Novel agents for advanced pancreatic cancer.Oncotarget · 2015Review
- Article
- Genomic alterations in pancreatic cancer and their relevance to therapy.World journal of gastrointestinal oncology · 2015Review
- Inhibition of malignant thyroid carcinoma cell proliferation by Ras and galectin-3 inhibitors.Cell death discovery · 2015Article
- Drugging the undruggable RAS: Mission possible?Nature reviews. Drug discovery · 2014Review
- A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Review
- Polymeric micelles: nanocarriers for cancer-targeted drug delivery.AAPS PharmSciTech · 2014Review
- Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.Cell death & disease · 2014Article
- Metabolism addiction in pancreatic cancer.Cell death & disease · 2014Review
- Article
- K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.Lung cancer (Amsterdam, Netherlands) · 2013Article
- PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel.Bioconjugate chemistry · 2013Article
- Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.Neuron · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constitutively active Ras proteins, their regulatory components, and overexpressed tyrosine kinase receptors that activate Ras, are frequently associated with cell transformation in human tumors. This suggests that functional Ras antagonists may have anti-tumor activity. Studies in rodent fibroblasts have shown that S-trans, transfarnesylthiosalicylic acid (FTS) acts as a rather specific nontoxic Ras antagonist, dislodging Ras from its membrane anchorage domains and accelerating its degradation. FTS is not a farnesyltransferase inhibitor, and does not affect Ras maturation. Here we demonstrate that FTS also acts as a functional Ras antagonist in human pancreatic cell lines that express activated K-Ras (Panc-1 and MiaPaCa-2). In Panc-1 cells, FTS at a concentration of 25-100 microM reduced the amount of Ras in a dose-dependent manner and interfered with serum-dependent and epidermal growth factor-stimulated ERK activation, thus inhibiting both anchorage-dependent and anchorage-independent growth of Panc-1 cells in vitro. FTS also inhibited tumor growth in Panc-1 xenografted nude mice, apparently without systemic toxicity. Daily FTS treatment (5 mg/kg intraperitoneally) in mice with tumors (mean volume 0.07 cm3) markedly decreased tumor growth (after treatment for 18 days, tumor volume had increased by only 23+/-30-fold in the FTS-treated group and by 127+/-66-fold in controls). These findings suggest that FTS represents a new class of functional Ras antagonists with potential therapeutic value.
Indexed as
Identifiers
10353601What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.